(0.31%) 5 115.95 points
(0.30%) 38 355 points
(0.37%) 15 986 points
(-0.97%) $83.04
(5.36%) $2.03
(0.34%) $2 355.10
(0.52%) $27.68
(4.17%) $960.55
(-0.27%) $0.932
(-0.47%) $10.97
(-0.57%) $0.796
(1.63%) $93.37
@ $0.850
発行日: 13 2月 2024 @ 05:20
リターン: 2.08%
前回のシグナル: 2月 13 - 00:52
前回のシグナル:
リターン: -3.19 %
Live Chart Being Loaded With Signals
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis...
Stats | |
---|---|
本日の出来高 | 338 322 |
平均出来高 | 956 590 |
時価総額 | 82.54M |
EPS | $0 ( 2024-03-11 ) |
次の収益日 | ( $-0.0100 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.190 |
ATR14 | $0.00600 (0.68%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Kirk Sigurd | Sell | 118 702 | Stock Option (right to buy) |
2024-03-14 | Tyree James L | Sell | 10 251 | Common Stock |
2024-02-21 | Schlessinger Sam | Buy | 17 151 | Common Stock |
2024-02-21 | Schlessinger Sam | Sell | 8 506 | Common Stock |
2024-02-21 | Schlessinger Sam | Sell | 17 151 | Restricted Stock Units |
INSIDER POWER |
---|
22.78 |
Last 98 transactions |
Buy: 4 490 251 | Sell: 3 194 471 |
ボリューム 相関
Assertio Holdings Inc 相関
10 最も負の相関 | |
---|---|
SVAC | -0.96 |
TENX | -0.948 |
SIRI | -0.947 |
VWE | -0.943 |
GOEV | -0.94 |
LGMK | -0.94 |
JAGX | -0.939 |
MDXH | -0.934 |
LSXMK | -0.932 |
LSXMA | -0.932 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Assertio Holdings Inc 相関 - 通貨/商品
Assertio Holdings Inc 財務諸表
Annual | 2023 |
収益: | $152.07M |
総利益: | $96.82M (63.67 %) |
EPS: | $-4.67 |
FY | 2023 |
収益: | $152.07M |
総利益: | $96.82M (63.67 %) |
EPS: | $-4.67 |
FY | 2022 |
収益: | $156.23M |
総利益: | $137.49M (88.00 %) |
EPS: | $2.33 |
FY | 2021 |
収益: | $111.01M |
総利益: | $95.18M (85.74 %) |
EPS: | $-0.0300 |
Financial Reports:
No articles found.
Assertio Holdings Inc
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。